These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 11532109)

  • 21. Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.
    Wühl E; Mehls O; Schaefer F;
    Kidney Int; 2004 Aug; 66(2):768-76. PubMed ID: 15253732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.
    Ruggenenti P; Perna A; Gherardi G; Benini R; Remuzzi G
    Am J Kidney Dis; 2000 Jun; 35(6):1155-65. PubMed ID: 10845831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Proteinuria Lowering by Angiotensin-Converting Enzyme Inhibition Predicts Renal Survival in Children with CKD.
    van den Belt SM; Heerspink HJL; Gracchi V; de Zeeuw D; Wühl E; Schaefer F;
    J Am Soc Nephrol; 2018 Aug; 29(8):2225-2233. PubMed ID: 29930161
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F; Chiodini P; De Nicola L; Minutolo R; Zamboli P; Gallo C; Conte G
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.
    Ruggenenti P; Perna A; Gherardi G; Garini G; Zoccali C; Salvadori M; Scolari F; Schena FP; Remuzzi G
    Lancet; 1999 Jul; 354(9176):359-64. PubMed ID: 10437863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus.
    Ha SK; Yong Lee S; Su Park H; Ho Shin J; Jung Kim S; Hun Kim D; Rae Kim K; Yung Lee H; Suk Han D
    Nephrol Dial Transplant; 2000 Oct; 15(10):1617-23. PubMed ID: 11007831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strict blood-pressure control and progression of renal failure in children.
    ; Wühl E; Trivelli A; Picca S; Litwin M; Peco-Antic A; Zurowska A; Testa S; Jankauskiene A; Emre S; Caldas-Afonso A; Anarat A; Niaudet P; Mir S; Bakkaloglu A; Enke B; Montini G; Wingen AM; Sallay P; Jeck N; Berg U; Caliskan S; Wygoda S; Hohbach-Hohenfellner K; Dusek J; Urasinski T; Arbeiter K; Neuhaus T; Gellermann J; Drozdz D; Fischbach M; Möller K; Wigger M; Peruzzi L; Mehls O; Schaefer F
    N Engl J Med; 2009 Oct; 361(17):1639-50. PubMed ID: 19846849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.
    Ruggenenti P; Perna A; Loriga G; Ganeva M; Ene-Iordache B; Turturro M; Lesti M; Perticucci E; Chakarski IN; Leonardis D; Garini G; Sessa A; Basile C; Alpa M; Scanziani R; Sorba G; Zoccali C; Remuzzi G;
    Lancet; 2005 Mar 12-18; 365(9463):939-46. PubMed ID: 15766995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease.
    Sasongko TH; Nagalla S; Ballas SK
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009191. PubMed ID: 23543572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease.
    Kent DM; Jafar TH; Hayward RA; Tighiouart H; Landa M; de Jong P; de Zeeuw D; Remuzzi G; Kamper AL; Levey AS
    J Am Soc Nephrol; 2007 Jun; 18(6):1959-65. PubMed ID: 17475813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy.
    Bakris GL; Weir MR; DeQuattro V; McMahon FG
    Kidney Int; 1998 Oct; 54(4):1283-9. PubMed ID: 9767545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients.
    Yokoyama H; Tomonaga O; Hirayama M; Ishii A; Takeda M; Babazono T; Ujihara U; Takahashi C; Omori Y
    Diabetologia; 1997 Apr; 40(4):405-11. PubMed ID: 9112017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
    Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
    J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
    Esnault VL; Ekhlas A; Nguyen JM; Moranne O
    Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additive antiproteinuric effect of combination therapy with ACE inhibitor and angiotensin II receptor antagonist: differential short-term response between IgA nephropathy and diabetic nephropathy.
    Kim MJ; Song JH; Suh JH; Lee SW; Kim GA
    Yonsei Med J; 2003 Jun; 44(3):463-72. PubMed ID: 12833584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is the antiproteinuric response to inhibition of the renin-angiotensin system less effective during the night?
    Buter H; Hemmelder MH; van Paassen P; Navis G; de Zeeuw D; de Jong PE
    Nephrol Dial Transplant; 1997; 12 Suppl 2():53-6. PubMed ID: 9269701
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.